Effect of bone marrow disease on hematologic toxicity and response to [177Lu]Lu-PSMA-617 therapy: insights from PSMA-PET/CT imaging
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-025-07541-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Nuno Borges und 11 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA. nborges2@bwh.harvard.edu. Hauptthemen laut MEDLINE: Dipeptides, Positron Emission Tomography Computed Tomography, Heterocyclic Compounds, 1-Ring, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Despite the effectiveness of [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC), hematologic toxicity remains a concern, particularly in patients with bone metastases. This study evaluated whether the extent, intensity, and heterogeneity of bone disease on pretreatment PSMA-PET/CT were associated with hematologic toxicity, PSA response, and overall survival (OS) in mCRPC patients treated with [177Lu]Lu-PSMA-617. METHODS: This retrospective study included 96 mCRPC patients who underwent pretreatment PSMA-PET/CT and received standard-of-care [177Lu]Lu-PSMA-617. Hematologic toxicity, PSA responses, and OS were analyzed in relation to quantitative PET parameters, including tumor volume, SUVmean, and heterogeneity of PSMA uptake in bone metastases. RESULTS: Clinically significant hematologic toxicity occurred in 19 patients (19.8%). Treatment discontinuation was more likely in those with a significantly higher (p = 0.007) percentage of total bone volume with PSMA-avid disease (median 28% vs. 1.7%). Those requiring dose delays or reductions (median 21% vs. 1.5%), blood transfusions (median 21% vs. 1.4%), and platelet transfusions (median 32% vs. 1.8%) also exhibited higher median percentages of total bone volume involvement (all p 50% difference between PSMA-low and PSMA-high bone disease was associated with significantly shorter OS (p < 0.001). CONCLUSION: Extensive PSMA-avid bone involvement was associated with increased hematologic toxicity in mCRPC treated with [177Lu]Lu-PSMA-617. Greater heterogeneity in PSMA uptake correlated with lower PSA50 response and OS but not hematologic toxicity. Careful patient selection and monitoring are needed, particularly in those with widespread bone disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA. nborges2@bwh.harvard.edu.
- Brigham and Women's Hospital, 75 Francis Street, Boston, Boston, MA, USA. nborges2@bwh.harvard.edu.
- Harvard Medical School, 25 Shattuck Street, Boston, MA, USA. nborges2@bwh.harvard.edu.
- School of Medicine and Health Sciences, George Washington University, 2300 I St NW, Washington, DC, USA.
- Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA.
- Harvard Medical School, 25 Shattuck Street, Boston, MA, USA.
ORCID-Profile: Nuno Borges
Zitieren
APA
Borges, N., Losee, M., Liu, M., Cheng, S. C., Könik, A., Ritzer, J., Wolanski, A., Ng, T. S. C., Choudhury, A. D., Taplin, M. E., Ravi, P., & Jacene, H. (2026). Effect of bone marrow disease on hematologic toxicity and response to [177Lu]Lu-PSMA-617 therapy: insights from PSMA-PET/CT imaging. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07541-3
Vancouver
Borges N, Losee M, Liu M, Cheng SC, Könik A, Ritzer J, et al. Effect of bone marrow disease on hematologic toxicity and response to [177Lu]Lu-PSMA-617 therapy: insights from PSMA-PET/CT imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07541-3
BibTeX
@article{Borges2026,
author = {Borges, Nuno and Losee, Meryam and Liu, Mofei and Cheng, Su-Chun and Könik, Arda and Ritzer, Jolivette and Wolanski, Andrew and Ng, Thomas S C and Choudhury, Atish D and Taplin, Mary-Ellen and Ravi, Praful and Jacene, Heather},
title = {Effect of bone marrow disease on hematologic toxicity and response to [177Lu]Lu-PSMA-617 therapy: insights from PSMA-PET/CT imaging},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-025-07541-3}
}
EUVIMED